Extracellular Vesicle (EVs) Associated Non-Coding RNAs in Lung Cancer and Therapeutics

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2022 Nov 11

PMID 36362424

Authors

Anjugam Paramanantham

Rahmat Asfiya

Siddharth Das

Grace McCully

Akhil Srivastava

Affiliations

Soon will be listed here.

Abstract

Lung cancer is one of the most lethal forms of cancer, with a very high mortality rate. The precise pathophysiology of lung cancer is not well understood, and pertinent information regarding the initiation and progression of lung cancer is currently a crucial area of scientific investigation. Enhanced knowledge about the disease will lead to the development of potent therapeutic interventions. Extracellular vesicles (EVs) are membrane-bound heterogeneous populations of cellular entities that are abundantly produced by all cells in the human body, including the tumor cells. A defined class of EVs called small Extracellular Vesicles (sEVs or exosomes) carries key biomolecules such as RNA, DNA, Proteins and Lipids. Exosomes, therefore, mediate physiological activities and intracellular communication between various cells, including constituent cells of the tumor microenvironment, namely stromal cells, immunological cells, and tumor cells. In recent years, a surge in studying tumor-associated non-coding RNAs (ncRNAs) has been observed. Subsequently, studies have also reported that exosomes abundantly carry different species of ncRNAs and these exosomal ncRNAs are functionally involved in cancer initiation and progression. Here, we discuss the function of exosomal ncRNAs, such as miRNAs and long non-coding RNAs, in the pathophysiology of lung tumors. Further, the future application of exosomal-ncRNAs in clinics as biomarkers and therapeutic targets in lung cancer is also discussed due to the multifaceted influence of exosomes on cellular physiology.

Citing Articles

The NcRNA/Wnt axis in lung cancer: oncogenic mechanisms, remarkable indicators and therapeutic targets.

Zhong Y, He J, Huang C, Lai H, Li X, Zheng C J Transl Med. 2025; 23(1):326.

PMID: 40087753 DOI: 10.1186/s12967-025-06326-4.

Current advance of nanotechnology in diagnosis and treatment for malignant tumors.

Wang B, Hu S, Teng Y, Chen J, Wang H, Xu Y Signal Transduct Target Ther. 2024; 9(1):200.

PMID: 39128942 PMC: 11323968. DOI: 10.1038/s41392-024-01889-y.

Exosomal LncRNAs and CircRNAs in lung cancer: Emerging regulators and potential therapeutic targets.

Li X, Wu Y, Jin Y Noncoding RNA Res. 2024; 9(4):1069-1079.

PMID: 39022675 PMC: 11254510. DOI: 10.1016/j.ncrna.2024.06.010.

Exosomal microRNAs in lung cancer: a narrative review.

Zhang Z, Lin F, Wu W, Jiang J, Zhang C, Qin D Transl Cancer Res. 2024; 13(6):3090-3105.

PMID: 38988916 PMC: 11231775. DOI: 10.21037/tcr-23-2319.

Pushing Forward the DNA Walkers in Connection with Tumor-Derived Extracellular Vesicles.

Liu Q, Zhang Q, Yao Z, Yi G, Kang Y, Qiu Y Int J Nanomedicine. 2024; 19:6231-6252.

PMID: 38915916 PMC: 11194468. DOI: 10.2147/IJN.S464895.

References

Kim D, Kang B, Kim O, Choi D, Lee J, Kim S . EVpedia: an integrated database of high-throughput data for systemic analyses of extracellular vesicles. J Extracell Vesicles. 2013; 2. PMC: 3760654. DOI: 10.3402/jev.v2i0.20384. View

Hanson P, Cashikar A . Multivesicular body morphogenesis. Annu Rev Cell Dev Biol. 2012; 28:337-62. DOI: 10.1146/annurev-cellbio-092910-154152. View

Qiu J, Lin X, Tang X, Zheng T, Lin Y, Hua K . Exosomal Metastasis‑Associated Lung Adenocarcinoma Transcript 1 Promotes Angiogenesis and Predicts Poor Prognosis in Epithelial Ovarian Cancer. Int J Biol Sci. 2018; 14(14):1960-1973. PMC: 6299373. DOI: 10.7150/ijbs.28048. View

Santangelo L, Giurato G, Cicchini C, Montaldo C, Mancone C, Tarallo R . The RNA-Binding Protein SYNCRIP Is a Component of the Hepatocyte Exosomal Machinery Controlling MicroRNA Sorting. Cell Rep. 2016; 17(3):799-808. DOI: 10.1016/j.celrep.2016.09.031. View

Domvri K, Petanidis S, Anestakis D, Porpodis K, Bai C, Zarogoulidis P . Exosomal lncRNA PCAT-1 promotes Kras-associated chemoresistance via immunosuppressive miR-182/miR-217 signaling and p27/CDK6 regulation. Oncotarget. 2020; 11(29):2847-2862. PMC: 7381096. DOI: 10.18632/oncotarget.27675. View

Mayor S, Pagano R . Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol. 2007; 8(8):603-12. PMC: 7617177. DOI: 10.1038/nrm2216. View

Liu Y, Dou M, Song X, Dong Y, Liu S, Liu H . The emerging role of the piRNA/piwi complex in cancer. Mol Cancer. 2019; 18(1):123. PMC: 6688334. DOI: 10.1186/s12943-019-1052-9. View

Pathan M, Fonseka P, Chitti S, Kang T, Sanwlani R, Van Deun J . Vesiclepedia 2019: a compendium of RNA, proteins, lipids and metabolites in extracellular vesicles. Nucleic Acids Res. 2018; 47(D1):D516-D519. PMC: 6323905. DOI: 10.1093/nar/gky1029. View

Tao Y, Tang Y, Yang Z, Wu F, Wang L, Yang L . Exploration of Serum Exosomal LncRNA TBILA and AGAP2-AS1 as Promising Biomarkers for Diagnosis of Non-Small Cell Lung Cancer. Int J Biol Sci. 2020; 16(3):471-482. PMC: 6990900. DOI: 10.7150/ijbs.39123. View

10.

Chen X, Wang Z, Tong F, Dong X, Wu G, Zhang R . lncRNA UCA1 Promotes Gefitinib Resistance as a ceRNA to Target FOSL2 by Sponging miR-143 in Non-small Cell Lung Cancer. Mol Ther Nucleic Acids. 2020; 19:643-653. PMC: 6965519. DOI: 10.1016/j.omtn.2019.10.047. View

11.

Yin K, Wang S, Zhao R . Exosomes from mesenchymal stem/stromal cells: a new therapeutic paradigm. Biomark Res. 2019; 7:8. PMC: 6450000. DOI: 10.1186/s40364-019-0159-x. View

12.

Soto-Heredero G, Baixauli F, Mittelbrunn M . Interorganelle Communication between Mitochondria and the Endolysosomal System. Front Cell Dev Biol. 2017; 5:95. PMC: 5681906. DOI: 10.3389/fcell.2017.00095. View

13.

Wu L, Pu X, Wang Q, Cao J, Xu F, Xu L . miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9. Oncol Lett. 2016; 11(2):945-952. PMC: 4734049. DOI: 10.3892/ol.2015.4000. View

14.

Bebelman M, Smit M, Pegtel D, Baglio S . Biogenesis and function of extracellular vesicles in cancer. Pharmacol Ther. 2018; 188:1-11. DOI: 10.1016/j.pharmthera.2018.02.013. View

15.

Kulkarni B, Gondaliya P, Kirave P, Rawal R, Jain A, Garg R . Exosome-mediated delivery of miR-30a sensitize cisplatin-resistant variant of oral squamous carcinoma cells via modulating Beclin1 and Bcl2. Oncotarget. 2020; 11(20):1832-1845. PMC: 7244014. DOI: 10.18632/oncotarget.27557. View

16.

Liu B, Wang R, Liu H . mir-126-5p Promotes Cisplatin Sensitivity of Non-Small-Cell Lung Cancer by Inhibiting ADAM9. Biomed Res Int. 2021; 2021:6622342. PMC: 8147552. DOI: 10.1155/2021/6622342. View

17.

Schulz-Siegmund M, Aigner A . Nucleic acid delivery with extracellular vesicles. Adv Drug Deliv Rev. 2021; 173:89-111. DOI: 10.1016/j.addr.2021.03.005. View

18.

Cazzoli R, Buttitta F, Di Nicola M, Malatesta S, Marchetti A, Rom W . microRNAs derived from circulating exosomes as noninvasive biomarkers for screening and diagnosing lung cancer. J Thorac Oncol. 2013; 8(9):1156-62. PMC: 4123222. DOI: 10.1097/JTO.0b013e318299ac32. View

19.

Pang K, Frith M, Mattick J . Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. Trends Genet. 2005; 22(1):1-5. DOI: 10.1016/j.tig.2005.10.003. View

20.

Keller S, Sanderson M, Stoeck A, Altevogt P . Exosomes: from biogenesis and secretion to biological function. Immunol Lett. 2006; 107(2):102-8. DOI: 10.1016/j.imlet.2006.09.005. View